Discover Biotech Webinar Pharma FDA & EMA ONCOLife Contact

ONCOLife

PHERGain Data Support Chemo-Free Treatment With 90% Five-Year RFS in Breast Cancer

ONCOLife

Targeting RNase H2 Exposes a New Therapeutic Vulnerability in Triple-Negative Breast Cancer

ONCOLife

ALK Mutation Emerges as a Potential Biomarker for Pan-Cancer Immunotherapy Benefit

Clinical Trials

Misinformation Drives Over 16 Million Americans Toward High Skin Cancer Risk

ONCOLife

Restoring Proteostasis May Boost T Cell Function and Open a New Route for Immunotherapy

Clinical Trials

Phase 3 MagnetisMM-5 Trial Supports Earlier Use of Elranatamab in Relapsed Myeloma

ONCOLife

Real-World Analysis Links Community Oncology Care to Longer Survival in Multi-Cancer

Clinical Trials

Dual Pathway Blockade Achieves 40% Response in Clear Cell Gynaecological Cancer

ONCOLife Issues

Featured Articles

FDA Approves Bizengri as First Targeted Therapy for NRG1 Fusion+ Cholangiocarcinoma

9 May 2026

The FDA has approved zenocutuzumab-zbco (BIZENGRI) for adults with advanced, unresectable or metastatic NRG1 fusion-positive cholangiocarcinoma after prior systemic therapy. In the Phase 2 eNRGy trial, the confirmed ORR was 36.8%...

Trending Articles

FDA Grants Breakthrough Status to First Urine-Based Multi-Cancer Early Detection Test

Daraxonrasib Doubles Overall Survival in Previously Treated Metastatic Pancreatic Cancer

ONCOLife

15 April 2026

AI Nodule Detection Helps Sarasota Memorial Reach 75% Early Lung Cancer Diagnosis

AI

15 April 2026

Illumina Launch 100 K Genome Effort to Advance Cancer and Rare Disease Research

AI

15 April 2026

Zenocutuzumab Gains NCCN Support as FDA Review Advances in Cholangiocarcinoma

FDA & EMA

15 April 2026

Phase 2 Data Position Trastuzumab Pamirtecan as a Promising Option in Endometrial Cancer

Mocertatug Rezetecan Shows Strong Responses in Ovarian and Endometrial Cancers

FDA & EMA

12 April 2026

FDA Grants Priority Review to Ifinatamab Deruxtecan in Pretreated ES-SC Lung Cancer

FDA & EMA

13 April 2026

MD Anderson Study Identifies DPY30 as Therapeutic Target in Pancreatic Cancer

ONCOLife

11 April 2026

Blocking DHODH Helps Triple Combination Overcome Resistance in Lung Cancer

ONCOLife

10 April 2026

New Strategy Blocks NMD, Unmasks Hidden Tumor Antigens, and Boosts Immunotherapy

Neladalkib Reaches FDA Review for TKI-Pretreated ALK+ Non-Small Cell Lung Cancer

FDA & EMA

9 April 2026

New Radio-Theranostic Promises to Broaden Targeted Radiation in Solid Tumors

ONCOLife

4 April 2026

FDA Grants Breakthrough Status to WU-CART-007 for T-Cell Leukemias and Lymphomas

FDA & EMA

1 April 2026

New IHC Biomarker Test Predicts Which Gastric Cancer Patients Benefit from Immunotherapy

ONCOLife

30 March 2026